Figure 1.

The expression of GOLT1B in multiple cancers. (A) Increased (red) or decreased (blue) expression of GOLT1B in different cancer tissues, compared with normal tissues in Oncomine. The number in each grid represents the amount of datasets. (B) Expression levels of GOLT1B in different cancer types from TCGA data in TIMER2. (C) Expression difference between the tumor tissues and normal tissues of the GTEx (tumors without normal tissues in TCGA). (D) The expression level of GOLT1B total protein in cancers of CPTAC data set. *P < 0.05,**P < 0.01. (E) Based on the TCGA data, the expression levels of the GOLT1B gene were analyzed by the main pathological stages (stages I, II, III, and IV) of ACC, BLCA, LUAD, OV, and UCS. Log₂(TPM +1) was applied for the log scale. ACC: adrenocortical carcinoma; BLCA: bladder urothelial carcinoma; BRCA: breast invasive carcinoma, CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: cholangiocarcinoma; COAD: colon adenocarcinoma, DLBC: lymphoid neoplasm diffuse large B-cell lymphoma; ESCA: esophageal carcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LAML: acute myeloid leukemia; LGG: brain lower grade glioma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; MESO: mesothelioma; OV: ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PCPG: pheochromocytoma and paraganglioma; PRAD: prostate adenocarcinoma; READ: rectum adenocarcinoma; SARC: sarcoma; SKCM: skin cutaneous melanoma; STAD: stomach adenocarcinoma; TGCT: testicular germ cell tumors; THCA: thyroid carcinoma; THYM: thymoma; UCEC: uterine corpus endometrial carcinoma; UCS: uterine carcinosarcoma; UVM: uveal melanoma.